Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LETTER TO THE EDITOR

Heart rate at presentation of COVID-19: Can SARS-CoV-2 be a cause of dysautonomia?

Frequência cardíaca na apresentação clínica de COVID-19: pode a SARS-CoV-2 ser uma causa de disautonomia?

To the Editor:

Respiratory infections usually lead to a physiological response mediated by the autonomic nervous system, which generally includes some degree of tachycardia. Our aim was to investigate the autonomic response in patients with COVID-19 based on the relationship between heart rate (HR), temperature (T²) and oxygen saturation (SatO₂) in the initial assessment at the emergency department. This retrospective, single-center study based on a large cohort of consecutive patients with confirmed diagnosis of SARS-CoV-2 infection by polymerase chain reaction, was conducted from 1 March to 20 April 2020 in a tertiary hospital in Madrid (Spain).

A total of 2757 patients (53.9% male, mean age 64.2±15.6 years) were included in the present analysis (detailed baseline characteristics are shown in Table 1). Among them, 78.1% required hospital admission, with 6.5% requiring admission to critical care units. During a median follow-up of 59 (50-66) days, mortality was 22.3%. Patients in the lowest HR quartiles were older, had more comorbidities and showed higher mortality during follow-up (Figure 1A). Although the proportion of HR lowering drugs was higher in this group, the results were similar in patients who did not take them.

A more detailed analysis showed that HR did not have a significant correlation with SatO₂ at admission (Pearson’s correlation coefficient -0.01, p=0.596, Figure 1B), although it did reveal a weak significant correlation with temperature (Pearson’s correlation coefficient 0.155, p<0.001, Figure 1C).

Since the beginning of the pandemic, multiple neurological manifestations of SARS-CoV-2 infection have been described, ranging from anosmia or dysgeusia to more serious conditions such as Guillain-Barré. However, evidence about its ability to cause dysautonomia is lacking. Although dysautonomia is linked to chronic diseases such as diabetes or Parkinson, cases associated with viral infections (including human immunodeficiency virus, hepatitis C, Epstein-Barr virus or Coxsackie) have also been described. Several studies have demonstrated that SARS-CoV-2 may affect the nervous system, with a special affinity for the medullary structures and the brainstem. Both areas show a strong expression of angiotensin-converting-enzyme-2 and are closely linked to the autonomic nervous system and interoception.

One of the most surprising aspects of COVID-19 pneumonia is the lack of dyspnea in patients with very low levels of blood oxygen. Some authors use the term “happy hypoxemia” to describe this dissociation. In the Wuhan cohort, only 19% of the patients infected with SARS-CoV2 reported dyspnea; 62% of the patients with severe disease (and approximately half of those who were intubated, ventilated, or died) did not present with dyspnea. In our setting, the proportion of patients with dyspnea was less than 50%.

Besides, also in favor of COVID-19-associated dysautonomia, cases of relative bradycardia (inappropriately low HR in response to an increase in temperature) have been described, however the pathophysiology is not entirely clear. Among the postulated mechanisms are the increase in vagal tone, a direct effect on the myocardium and sinoatrial node or mediated by the cytokine cascade. Some authors even postulate that the presence of sinus bradycardia may be a red flag that precedes the clinical worsening of the patient. The absence of the development of proportionate tachycardia based on SatO₂ at admission supports the existence of a certain degree of dysautonomia. This could partly explain the good clinical tolerance to hypoxia in the initial stages of the disease. However, worse outcomes in patients with lower HRs may reflect major autonomic involvement in patients with severe disease and may be associated with worse prognosis.

Although more studies are needed, dysautonomia must not delay appropriate management of COVID-19 patients (in the case of hypoxia-dyspnea dissociation). In fact, it may signal clinical worsening.
Table 1  Baseline characteristics and outcomes.

|                      | All patients (n=2757) | First quartile (n=710) | Second quartile (n=674) | Third quartile (n=713) | Fourth quartile (n=660) | p value |
|----------------------|-----------------------|------------------------|-------------------------|------------------------|-------------------------|---------|
| Age (years)          | 64.2±15.6             | 72.6±17.0              | 66.9±18.2               | 62.7±18.2              | 54.0±20.8               | <0.001  |
| Male gender (%)      | 1524 (55.3)           | 391 (55.1)             | 371 (55.0)              | 401 (56.2)             | 361 (54.7)              | 0.943   |
| Time symptoms-diagnosis (days) | 6.4±5.3              | 5.9±5.4                | 6.4±5.2                 | 6.7±5.2                | 6.7±5.4                 | 0.014   |
| Hypertension (%)     | 1271 (46.1)           | 419 (59.0)             | 324 (48.1)              | 298 (41.8)             | 230 (34.9)              | <0.001  |
| Diabetes (%)         | 530 (19.2)            | 160 (22.5)             | 150 (22.3)              | 125 (17.5)             | 95 (14.4)               | <0.001  |
| Dyslipidemia (%)     | 1051 (38.1)           | 334 (47.0)             | 276 (41.0)              | 247 (34.6)             | 194 (29.4)              | <0.001  |
| Coronary heart disease (%) | 149 (5.4)            | 70 (9.9)               | 40 (5.9)                | 24 (3.4)               | 15 (2.3)                | <0.001  |
| Heart failure (%)    | 44 (11.1)             | 1 (1.0)                | 5 (5.1)                 | 13 (1.1)               | 25 (25.3)               | <0.001  |
| Atrial fibrillation (%) | 246 (8.9)            | 108 (15.2)             | 59 (8.8)                | 39 (5.5)               | 40 (6.1)                | <0.001  |
| Chronic treatment with BB (%) | 391 (14.2)          | 161 (22.7)             | 103 (15.3)              | 78 (10.9)              | 49 (7.4)                | <0.001  |
| Chronic treatment with CA (%) | 361 (13.1)          | 118 (16.6)             | 105 (15.6)              | 75 (10.5)              | 63 (9.6)                | <0.001  |
| HR (bpm) at admission | 93.6±19.7            | 70.4±8.1               | 86.6±3.3                | 99.2±3.9               | 119.9±12.9              | <0.001  |
| SBP (mmHg) at admission | 129.0±21.4           | 131.2±22.3             | 129.5±21.6              | 128.6±20.3             | 126.3±20.5              | 0.002   |
| SatO2 (%) at admission | 92.1±6.3             | 92.2±6.4               | 91.9±5.7                | 92.3±6.1               | 92.1±6.8                | 0.676   |
| Temp. (°C) at admission | 36.9±0.9             | 36.7±0.9               | 36.9±0.9                | 37.0±0.9               | 37.1±1.0                | <0.001  |
| CRP (max)            | 106.7                 | 99.8                   | 115.5                   | 106.4                  | 110.5                   | 0.018   |
| (42.1-204.3)         | (40.9-183.4)          | (46.9-214.5)           | (42.1-207.9)            | (39.7-217.9)           |                         |         |
| PE (%)               | 76 (2.8)              | 10 (1.4)               | 17 (2.5)                | 27 (3.8)               | 22 (3.3)                | 0.035   |
| Arrhythmias during admission (%) | 118 (4.3)          | 37 (5.2)               | 21 (3.1)                | 29 (4.1)               | 31 (4.7)                | 0.252   |
| Heart failure during admission (%) | 75 (2.7)             | 34 (4.8)               | 14 (2.1)                | 14 (2.0)               | 13 (2.0)                | 0.001   |
| Mechanical ventilation (%) | 170 (6.2)            | 32 (4.5)               | 40 (5.9)                | 54 (7.6)               | 44 (6.7)                | 0.107   |
| Death (%)            | 616 (22.3)            | 188 (26.5)             | 176 (26.1)              | 142 (19.9)             | 110 (16.7)              | <0.001  |

Figure 1  Panel A: Kaplan Meier survival analysis stratified according to the heart rate quartile at hospital admission. Panel B: Scatter plot showing no correlation between SatO2 and heart rate at admission. Panel C: Scatter plot showing a weak correlation between temperature and heart rate at admission.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Eshak N, Abdelnabi M, Ball S, et al. Dysautonomia: an overlooked neurological manifestation in a critically ill COVID-19 patient. Am J Med Sci. 2020;360:427–9.
2. González-Duarte A, Norcliffe-Kaufmann L. Is ‘happy hypoxia’ in COVID-19 a disorder of autonomic interoception? A hypothesis. Clin Auton Res. 2020;30:331–3.
3. Wei-Jie G, Zheng-yi N, Yu H, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
4. Borobia AM, Carcas AJ, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020;9:1733.
5. Capoferri G, Oshhoff M, Egli A, et al. Relative bradycardia in patients with coronavirus disease 2019 (COVID-19). Clin Microbiol Infect. 2020. S1198-743X(20)30495-X.
6. Amaratunga EA, Corwin DS, Moran L, et al. Bradycardia in patients with COVID-19: a calm before the storm? Cureus. 2020;12:e8599.

Andrea Severo Sánchez, Juan R. Rey, Ángel Manuel Iniesta, Jose L. Merino, Sergio Castrejón-Castrejón, Esteban López-de-Sá, Juan Caro-Codón*

Cardiology Department, Hospital Universitario La Paz, Madrid, Spain

*Corresponding author.  
E-mail address: juancarocd@gmail.com (J. Caro-Codón).